Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 5/20 | 0.61 |
| ▸ | SIRT1 | Q96EB6 | 4/20 | 0.56 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.56 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.55 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.55 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.55 |
| ▸ | CPB1 | P15086 | 1/20 | 0.54 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.54 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.54 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.54 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22055423 | 0.99 | SIRT2 (0.63) | SIRT2SIRT1FOLH1SIRT3CAPN1 | |
| SCHEMBL15084702 | 0.98 | SIRT2 (0.59) | SIRT2SIRT1FOLH1SIRT3CAPN1 | |
| SCHEMBL14240585 | 0.96 | SIRT2 (0.58) | SIRT2SIRT1FOLH1SIRT3CAPN1 | |
| SCHEMBL14642695 | 0.95 | SIRT2 (0.64) | SIRT2SIRT1SIRT3CAPN1CAPN2 | |
| SCHEMBL14642694 | 0.95 | SIRT2 (0.59) | SIRT2SIRT1FOLH1SIRT3CAPN1 | |
| SCHEMBL20980386 | 0.94 | CPB1 (0.60) | SIRT2SIRT1FOLH1SIRT3CPB1 | |
| SCHEMBL14642785 | 0.94 | SIRT2 (0.57) | SIRT2SIRT1FOLH1SIRT3CAPN1 | |
| SCHEMBL14642700 | 0.94 | SIRT2 (0.57) | SIRT2SIRT1FOLH1SIRT3CAPN1 | |
| SCHEMBL14642788 | 0.94 | SIRT2 (0.62) | SIRT2SIRT1SIRT3CAPN1CAPN2 | |
| SCHEMBL18653805 | 0.93 | SIRT2 (0.57) | SIRT2SIRT1SIRT3CAPN1CAPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4171577-B1 | PROCESS FOR SYNTHESIZING TARGETING MOLECULES | BRISTOL MYERS SQUIBB CO (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20230250053-A1 | PROCESS FOR SYNTHESIZING TARGETING MOLECULES | BRISTOL-MYERS SQUIBB COMPANY | 2023-08-10 | — | — | US | disclosed |
| EP-4171577-A1 | PROCESS FOR SYNTHESIZING TARGETING MOLECULES | Bristol-Myers Squibb Company (US) | 2023-05-03 | — | — | EP | disclosed |
| US-10669229-B2 | Compounds for targeting drug delivery and enhancing siRNA activity | NITTO DENKO CORPORATION (JP) | 2020-06-02 | — | — | US | disclosed |
| EP-2998289-B1 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING SIRNA ACTIVITY | NITTO DENKO CORP (JP) | 2019-08-07 | — | — | EP | disclosed |
| US-10196637-B2 | Retinoid-lipid drug carrier | NITTO DENKO CORPORATION (JP) | 2019-02-05 | — | — | US | disclosed |
| US-10000447-B2 | Compounds for targeting drug delivery and enhancing siRNA activity | NITTO DENKO CORPORATION (JP) | 2018-06-19 | — | — | US | disclosed |
| US-20170081663-A1 | RETINOID-LIPID DRUG CARRIER | NITTO DENKO CORPORATION (JP) | 2017-03-23 | — | — | US | disclosed |
| US-20170000893-A1 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY | NITTO DENKO CORP (JP) | 2017-01-05 | — | — | US | disclosed |
| US-20170001950-A1 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY | NITTO DENKO CORP (JP) | 2017-01-05 | — | — | US | disclosed |
| US-20130210744-A1 | TARGETING AGENT FOR CANCER CELL OR CANCER-ASSOCIATED FIBROBLAST | NITTO DENKO CORPORATION (JP) | 2013-08-15 | — | — | US | disclosed |
| US-20130171127-A1 | COMPOSITION FOR REGENERATING NORMAL TISSUE FROM FIBROTIC TISSUE | NITTO DENKO CORPORATION (JP) | 2013-07-04 | — | — | US | disclosed |
| US-20130171240-A1 | DRUG CARRIER AND DRUG CARRIER KIT FOR INHIBITING FIBROSIS | NITTO DENKO CORPORATION (JP) | 2013-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130171240-A1 | DRUG CARRIER AND DRUG CARRIER KIT FOR INHIBITING FIBROSIS | KIT, STRA6, HAVCR2 | SIRT2 1708/4885SIRT1 1340/4885FOLH1 513/4885 |
| US-10000447-B2 | Compounds for targeting drug delivery and enhancing siRNA activity | LDLR, RARG, FABP4 | SIRT2 2436/4885SIRT1 1811/4885FOLH1 783/4885 |
| US-20130171127-A1 | COMPOSITION FOR REGENERATING NORMAL TISSUE FROM FIBROTIC TISSUE | COL1A1, COL2A1, COL14A1 | SIRT2 2458/4885SIRT1 2562/4885FOLH1 1251/4885 |
| US-20170001950-A1 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY | LDLR, RARG, FABP4 | SIRT2 2436/4885SIRT1 1811/4885FOLH1 783/4885 |
| US-20170081663-A1 | RETINOID-LIPID DRUG CARRIER | RXRA, RXRG, LRAT | SIRT2 3072/4885SIRT1 3138/4885FOLH1 2079/4885 |
| US-20230250053-A1 | PROCESS FOR SYNTHESIZING TARGETING MOLECULES | RARG, RARA, RARB | SIRT2 3977/4885SIRT1 3363/4885FOLH1 784/4885 |
| US-20170000893-A1 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY | LDLR, RARG, FABP4 | SIRT2 2436/4885SIRT1 1811/4885FOLH1 783/4885 |
| US-10669229-B2 | Compounds for targeting drug delivery and enhancing siRNA activity | LDLR, RARG, FABP4 | SIRT2 2436/4885SIRT1 1811/4885FOLH1 783/4885 |
| US-20130210744-A1 | TARGETING AGENT FOR CANCER CELL OR CANCER-ASSOCIATED FIBROBLAST | FGFR2, FRS2, FOLR1 | SIRT2 2950/4885SIRT1 2979/4885FOLH1 45/4885 |
| US-10196637-B2 | Retinoid-lipid drug carrier | RXRA, RXRG, LRAT | SIRT2 3072/4885SIRT1 3138/4885FOLH1 2079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.